Clinical Trial Update: Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase [Phase 2]

View source ↗

Summary

Phase 2 trial update on dose escalation of liposomal amikacin for inhalation (ARIKAYCE) in cystic fibrosis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Arikayce (amikacin liposome inhalation suspension)

Snippet

Sponsor: Insmed Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2019-05-14